Biomarin

BioMarin's Novel Treatment Promises to Disrupt Competitors
Motley Fool
Wed, 02/26/20 - 10:45 am
Biomarin
gene therapy
valrox
hemophilia A
FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review
Motley Fool
Thu, 02/20/20 - 11:41 pm
FDA
Biomarin
priority review
valrox
gene therapy
hemophilia A
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
Mon, 02/17/20 - 11:33 pm
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World
Forbes
Thu, 02/6/20 - 11:37 pm
Biomarin
valrox
gene therapy
hemophilia A
BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy
Motley Fool
Thu, 01/16/20 - 11:27 pm
Biomarin
JPMHC 2020
drug pricing
valrox
hemophilia
BioMarin sets gene therapy sights beyond hemophilia
BioPharma Dive
Mon, 01/13/20 - 11:40 pm
Biomarin
hemophilia
gene therapy
These 3 Biotech Stocks Could Be Top Stocks in 2020
Motley Fool
Sun, 01/12/20 - 11:19 pm
Biomarin
Iovance
Immunomedics
A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations
Yahoo/Benzinga
Sat, 01/11/20 - 11:02 pm
JPMHC 2020
Bristol-Myers Squibb
Vertex Pharmaceuticals
Biomarin
Regeneron
Biogen
Alexion
Gilead Sciences
Amgen
Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles
Fierce Pharma
Thu, 12/19/19 - 01:11 pm
gene therapy
reimbursement
drug manufacturing
Bristol-Myers Squibb
Pfizer
Biomarin
Sarepta Therapeutics
Gilead Sciences
CAR-T
Value-based pricing for gene therapy? Maybe not ready for hemophilia
Biopharma Dive
Thu, 12/12/19 - 10:52 am
Biomarin
hemophilia
hemophilia A
gene therapy
valoctocogene roxaparvovec
uniQure
hemophilia B
etranadez
Here's Why BioMarin Pharmaceutical Leapt 10.2% in November
Motley Fool
Wed, 12/4/19 - 10:19 am
Biomarin
R&D
gene therapy
Europe
The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict
Yahoo/Benzinga
Sun, 10/20/19 - 05:18 pm
earnings
Eli Lilly
Alexion
Gilead Sciences
Biomarin
Edwards Lifesciences
Baxter International
Integra LifeSciences
Phathom Pharmaceuticals
IPOs
Foamix
Eton Pharmaceuticals
Melinta Therapeutics
Ligand Pharmaceuticals
BioMarin talks down worries on gene therapy data differences
Biopharma Dive
Tue, 09/10/19 - 11:39 pm
Biomarin
gene therapy
hemophilia A
valrox
BioMarin's Roller Coaster Continues
Yahoo/Motley Fool
Tue, 08/6/19 - 11:00 am
Biomarin
earnings
BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end
Fierce Biotech
Fri, 08/2/19 - 10:37 am
Biomarin
hemophilia
gene therapy
valoctocogene roxaparvovec
valrox
hemophilia A
Billions on the line: BioMarin bustles past enthused rival, planning to launch world’s first hemophilia A gene therapy
Endpoints
Mon, 07/8/19 - 08:13 pm
Biomarin
hemophilia A
gene therapy
FDA
Sangamo
Pfizer
Sangamo backs up early success for hemophilia gene therapy
Biopharma Dive
Sat, 07/6/19 - 01:36 pm
Sangamo
gene therapy
hemophilia A
SB-525
Pfizer
Spark Therapeutics
Biomarin
How BioMarin May Revolutionize the Hemophilia Treatment Market
Motley Fool
Tue, 05/28/19 - 11:25 pm
Biomarin
gene therapy
hemophilia A
valrox
BioMarin Isn't a "Gene Therapy Company"
Motley Fool
Wed, 05/1/19 - 11:38 pm
Biomarin
earnings
The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
Yahoo/Benzinga
Mon, 04/22/19 - 10:34 am
Concert Pharmaceuticals
Horizon Pharma
Edwards Lifesciences
Zimmer Biomet
Genfit
Precision Biosciences
Boston Scientific
AbbVie
Alexion
Bristol-Myers Squibb
Baxter
Biomarin
AtriCure
Biogen
Seattle Genetics
IPOs
earnings

Pages